Serial investors: Comforting figures for VC backers

The San Diego Business Journal profiles serial entrepreneur Randy Woods, who has raised $20 million so far to back Sequel Pharmaceuticals, a spin-off from NovaCardia. Woods had been the CEO of NovaCardia when it was sold to Merck for $364 million last fall. Earlier, Woods had run Corvas International, which was sold to Dendreon in '03 after a failed clinical trial. Woods' new venture is focused on developing an experimental therapy for arrhythmia.

What Woods finds exciting: "It's being on the edge of the technology that's the next newest and biggest thing." Sounds exciting, but Woods also notes that venture capitalists like to see familiar faces at the helm of those cutting-edge startups.

- read the article from the San Diego Business Journal

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."